Kris Saha leads a team joining NIH’s Somatic Cell Genome Editing Consortium
As gene editing therapies for macular degeneration and other visual disorders work their way into clinical trials, the University of Wisconsin–Madison is on the forefront of research into making sure they are safe and effective. Nine years ago, David Gamm, M.D., Ph.D., Director of the McPherson Eye Research Institute (MERI) and associate professor of ophthalmology …